Dr. Richard M. Stone on the Genetic Landscape in AML

Richard M. Stone, MD
Published: Thursday, Oct 06, 2016


Richard M. Stone, MD, chief of staff, program director, adult leukemia, institute physician, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses what is currently understood regarding the genetic landscape in acute myeloid leukemia (AML).
 
The number of mutations in any given patient’s blasts are probably lower in total in AML than they are in solid tumor patients, says Stone. The types of mutations can be subdivided into different categories, which may lead it self to the development of specific therapeutics.
 
Assessing mutations at the time of diagnosis also offers additional prognostic information, which is some cases can be used to decide on therapy.
 

Richard M. Stone, MD, chief of staff, program director, adult leukemia, institute physician, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses what is currently understood regarding the genetic landscape in acute myeloid leukemia (AML).
 
The number of mutations in any given patient’s blasts are probably lower in total in AML than they are in solid tumor patients, says Stone. The types of mutations can be subdivided into different categories, which may lead it self to the development of specific therapeutics.
 
Assessing mutations at the time of diagnosis also offers additional prognostic information, which is some cases can be used to decide on therapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x